Real‐life intraclass switch among IL‐17 inhibitors in psoriasis: results from a single‐centre, 24‐week, retrospective study

Journal of the European Academy of Dermatology and VenereologyVolume 36, Issue 11 p. e952-e953 Letter to the Editor Real-life intraclass switch among IL-17 inhibitors in psoriasis: results from a single-centre, 24-week, retrospective study E. Sotiriou, E. Sotiriou orcid.org/0000-0001-6235-4718 First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, GreeceSearch for more papers by this authorK. Bakirtzi, Corresponding Author K. Bakirtzi [email protected] orcid.org/0000-0001-5515-2536 First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, GreeceCorrespondence: B. Katerina. E-mail: [email protected]Search for more papers by this authorI. Papadimitriou, I. Papadimitriou orcid.org/0000-0002-8096-156X First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, GreeceSearch for more papers by this authorA. Tsentemeidou, A. Tsentemeidou orcid.org/0000-0002-8470-0682 First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, GreeceSearch for more papers by this authorN. Kougkas, N. Kougkas Fourth Department of Internal Medicine, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, GreeceSearch for more papers by this authorA. Panagopoulou, A. Panagopoulou First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, GreeceSearch for more papers by this authorD. Ioannides, D. Ioannides orcid.org/0000-0002-8997-9889 First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, GreeceSearch for more papers by this authorE. Vakirlis, E. Vakirlis First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, GreeceSearch for more papers by this author E. Sotiriou, E. Sotiriou orcid.org/0000-0001-6235-4718 First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, GreeceSearch for more papers by this authorK. Bakirtzi, Corresponding Author K. Bakirtzi [email protected] orcid.org/0000-0001-5515-2536 First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, GreeceCorrespondence: B. Katerina. E-mail: [email protected]Search for more papers by this authorI. Papadimitriou, I. Papadimitriou orcid.org/0000-0002-8096-156X First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, GreeceSearch for more papers by this authorA. Tsentemeidou, A. Tsentemeidou orcid.org/0000-0002-8470-0682 First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, GreeceSearch for more papers by this authorN. Kougkas, N. Kougkas Fourth Department of Internal Medicine, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, GreeceSearch for more papers by this authorA. Panagopoulou, A. Panagopoulou First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, GreeceSearch for more papers by this authorD. Ioannides, D. Ioannides orcid.org/0000-0002-8997-9889 First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, GreeceSearch for more papers by this authorE. Vakirlis, E. Vakirlis First Department of Dermatology and Venereology, Aristotle University of Thessaloniki, Thessaloniki, GreeceSearch for more papers by this author First published: 30 June 2022 https://doi.org/10.1111/jdv.18381Citations: 4 E. Sotiriou and K. Bakirtzi have equally distributed to the manuscript Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1Wang TS, Tsai TF. Biologics switch in psoriasis. Immunotherapy 2019; 11: 531– 541. 2Gasslitter I, Kirsten N, Augustin M et al. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. Arch Dermatol Res 2019; 311: 421– 424. 3Amschler K, Phillip S, Mohr J et al. Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab. Dermatol Online J 2020; 26: 13030. 4Bokor-Billmann T, Schäkel K. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis. J Dermatolog Treat 2019; 30: 216– 220. 5Georgakopoulos JR, Phung M, Ighani A, Yeung J. Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies. J Am Acad Dermatol 2018; 79: 155– 157. 6Kromer C, Wilsmann-Theis D, Gerdes S et al. Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker – a retrospective multicenter study. J Dermatolog Treat 2021; 32: 878– 882. 7Conti A, Peccerillo F, Amerio P et al. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. Br J Dermatol 2019; 180: 1547– 1548. 8Sherman S, Solomon Cohen E, Amitay-Laish I, Hodak E, Pavlovsky L. IL-17A inhibitor switching – efficacy of ixekizumab following secukinumab failure. A single-center experience. Acta Derm Venereol 2019; 99: 769– 773. 9Loft N, Bregnhøj A, Fage S et al. Effectiveness of brodalumab after previous treatment failure of interleukin-17A inhibitors in patients with psoriasis. Dermatol Ther 2021; 34: e15106. 10Georgakopoulos JR, Phung M, Ighani A, Lam K, Yeung J. Biologic switching between interleukin 17A antagonists secukinumab and ixekizumab: a 12-week, multicenter, retrospective study. J Eur Acad Dermatol Venereol 2019; 33: e7– e8. Citing Literature Volume36, Issue11November 2022Pages e952-e953 ReferencesRelatedInformation